Researchers suggest new follow-up model for breast cancer patients

The surveillance of breast cancer survivors has the potential to improve, from the perspective of both patients and the health system, according to new research.

International guidelines recommend annual follow-up mammograms for every woman after treatment for early breast cancer, regardless of the risk of her cancer returning. There is also no strong evidence to support annual mammography compared with other possible mammography schedules.

For postmenopausal women with moderate-prognosis, early breast cancer, less frequent surveillance may be more cost-effective, especially for those older than 70 years. This was demonstrated by researchers in the School of Population Health at the University of Adelaide in Australia and published in Value in Health (2014; doi:10.1016/j.jval.2014.07.002).

"Due to early diagnosis and improved treatment, the number of breast cancer survivors is increasing. All of these women will need follow-up mammography to detect recurrent or new disease," said the study's co-author, Professor Jon Karnon, PhD.

"But while the diagnosis and treatment have significantly improved the outlook for many cancer patients, approaches to cancer surveillance haven't changed. The results show that for younger postmenopausal women at moderate risk of breast cancer recurrence, annual follow-up screening for 5 years, with two yearly visits thereafter, appears to be cost-effective.

"For older women, a mammography schedule every 2 years is likely to be cost-effective, if women continue to attend follow-up mammography," he said.

The researchers based their findings on health service data and simulation modelling, enabling them to predict the long-term costs and health outcomes of alternative mammography schedules for women, based on the women's age and the features of their primary breast cancer.

"It's clear to us that the current one-size-fits-all international guideline of annual follow-up mammography may not be necessary for all women with early breast cancer," said study co-author Clinical Associate Professor Taryn Bessen, MBBS.

"This work highlights the potential benefit of tailoring follow-up to the risk of recurrence, and the use of modelling methods to help guide clinical practice in an evidence-based and pragmatic manner."

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs